Axelia Oncology is a biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response.

Axelia Oncology is developing AXA-042, a potent selective, systemically delivered, TLR2/6 agonist for solid tumour indications.

AXA-042 development is based on vaccine adjuvant research from the laboratory of Professor David Jackson at the Peter Doherty Institute for Infection and Immunity, University of Melbourne.


Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.